Selected article for: "human phase and long term"
Author: Meng, Fanping; Xu, Ruonan; Wang, Siyu; Xu, Zhe; Zhang, Chao; Li, Yuanyuan; Yang, Tao; Shi, Lei; Fu, Junliang; Jiang, Tianjun; Huang, Lei; Zhao, Peng; Yuan, Xin; Fan, Xing; Zhang, Ji-Yuan; Song, Jinwen; Zhang, Dawei; Jiao, Yanmei; Liu, Limin; Zhou, Chunbao; Maeurer, Markus; Zumla, Alimuddin; Shi, Ming; Wang, Fu-Sheng
Title: Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
  • Cord-id: f8r2jf67
  • Document date: 2020_8_27
    • ID: f8r2jf67
    Snippet: No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moder
    Document: No effective drug treatments are available for coronavirus disease 2019 (COVID-19). Host-directed therapies targeting the underlying aberrant immune responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors require clinical evaluation. We performed a parallel assigned controlled, non-randomized, phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous infusion of UC-MSCs (3 × 10(7) cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest computed tomography (CT) images, the PaO(2)/FiO(2) ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analyzed. No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. All patients recovered and were discharged. Our data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated. Phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs to reduce deaths and improve long-term treatment outcomes in patients with serious COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • activate inflammatory response and acute ards respiratory distress syndrome: 1
    • activate inflammatory response and acute respiratory syndrome: 1, 2, 3
    • activate inflammatory response suppress and acute ards respiratory distress syndrome: 1
    • activate inflammatory response suppress and acute respiratory syndrome: 1
    • acute ards respiratory distress syndrome and adipose tissue: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission symptom onset: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and admission symptom onset interval: 1
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute respiratory syndrome and adherent cell: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adipose tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and admission symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and admission symptom onset interval: 1, 2, 3
    • acute respiratory syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low plasma level: 1
    • adipose tissue and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission symptom onset and liver disease: 1